The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study

Introduction: This study compared the health and economic impact of the 21-valent pneumococcal conjugate vaccine (aPCV21) vs the 20-valent pneumococcal conjugate vaccine (PCV20) on invasive pneumococcal disease (IPD) and post-meningitis sequelae (PMS) among adults aged 65 years and older in the United Kingdom (UK). Methods: A published Markov model was used to simulate a single-cohort of vaccine-naive adults who became eligible for age-based vaccination at age 65 years, with uptake occurring over time. The cohort was followed until a maximum age of 100 years. Model inputs were derived from pub

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.